Author

Joseph M Wu

Professor of Biochemistry and Molecular Biology - Cited by 12,185 - cancer biology

Biography

Dr. Joseph M Wu is an Professor of Biochemistry and Molecular Research Professor of Urology Director, Master's Program - Biochemistry and Molecular Biology. Dr. Wu’s laboratory studies targets and mechanisms by which resveratrol, a polyphenol isolated from grapes, protects cardiovascular cell structure and function and prevents cancer. Due to the use of known carcinogens, all trainees must be at least 18 years old.
Title
Cited by
Year
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
A Deodhar, P Sliwinska-Stanczyk, H Xu, X Baraliakos, LS Gensler, ...Annals of the rheumatic diseases 80 (8), 1004-1013, 2021202
111
2021
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III …
V Strand, K de Vlam, JA Covarrubias-Cobos, PJ Mease, DD Gladman, ...RMD open 5 (1), e000808, 2019201
54
2019
Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study
P Nash, LC Coates, AJ Kivitz, PJ Mease, DD Gladman, ...Rheumatology and therapy 7, 553-580, 2020202
42
2020
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of …
C Charles-Schoeman, MH Buch, M Dougados, DL Bhatt, JT Giles, ...Annals of the rheumatic diseases 82 (1), 119-129, 2023202
39
2023
Nucleolin is a functional binding protein for salinomycin in neuroblastoma stem cells
F Wang, S Zhou, D Qi, SH Xiang, ET Wong, X Wang, E Fonkem, T Hsieh, ...Journal of the American Chemical Society 141 (8), 3613-3622, 2019201
33
2019
Social contact patterns and implications for infectious disease transmission–a systematic review and meta-analysis of contact surveys
A Mousa, P Winskill, OJ Watson, O Ratmann, M Monod, M Ajelli, A Diallo, ...Elife 10, e70294, 2021202
28
2021
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
JR Curtis, K Yamaoka, YH Chen, DL Bhatt, LM Gunay, N Sugiyama, ...Annals of the Rheumatic Diseases 82 (3), 331-343, 2023202
22
2023
Resveratrol suppresses prostate cancer epithelial cell scatter/invasion by targeting inhibition of hepatocyte growth factor (HGF) secretion by prostate stromal cells and …
T Hsieh, JM WuInternational Journal of Molecular Sciences (5), 1760, 2020202
21
2020
Trailblazing perspectives on targeting breast cancer stem cells
J Li, D Qi, TC Hsieh, JH Huang, JM Wu, E WuPharmacology & Therapeutics 223, 107800, 202
21
2021
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
P Nash, LC Coates, D Fleishaker, AJ Kivitz, PJ Mease, DD Gladman, ...The Lancet Rheumatology 3 (4), e270-e283, 2021202
19
2021
RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED>= 50 YEARS WITH RHEUMATOID ARTHRITIS AND>= 1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF …
C Charles-Schoeman, MH Buch, M Dougados, DL Bhatt, JT Giles, ...ANNALS OF THE RHEUMATIC DISEASES 81, 611-612, 2022202
18
2022
Malignancies in patients aged≥ 50 years with RA and≥ 1 additional cardiovascular risk factor: results from a Phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors
J Curtis, K Yamaoka, YH Chen, L Gunay, N SugiyamaArthritis Rheumatol 73 (suppl 10), 4060-4063, 2021202
15
2021
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised …
P Nash, PJ Mease, D Fleishaker, J Wu, LC Coates, F Behrens, ...The Lancet Rheumatology 3 (1), e28-e39, 2021202
14
2021
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
JF Merola, KA Papp, P Nash, J Gratacós, WH Boehncke, D Thaçi, ...Journal of the European Academy of Dermatology and Venereology 34 (12), 2809 …, 2020202
14
2020
Modelling the adjustment of COVID-19 response and exit from dynamic zero-COVID in China
K Leung, GM Leung, J WumedRxiv, 2022.12. 14.22283460, 2022202
13
2022
Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study
A Deodhar, P Sliwinska-Stanczyk, H Xu, X Baraliakos, L Gensler, ...Arthritis Rheumatol 72 (Suppl 10), 2020202
13
2020
Elucidating the inhibitory effect of resveratrol and its structural analogs on selected nucleotide-related enzymes
Y Wu, T Hsieh, JM Wu, X Wang, JS Christopher, AH Pham, JDL Swaby, ...Biomolecules 10 (9), 1223, 2020202
11
2020
Tumor PD-L1 induction by resveratrol/piceatannol may function as a Search, Enhance, and Engage (“SEE”) signal to facilitate the elimination of “cold, non-responsive” low PD-L1 …
TC Hsieh, JM WuInternational Journal of Molecular Sciences 20 (23), 5969, 2019201
10
2019
Control of DNA structure and function by phytochemicals/DNA interaction: Resveratrol/piceatannol induces Cu2+-independent, cleavage of supercoiled plasmid DNA
T Hsieh, HH Chao, JM WuFree Radical Biology and Medicine 147, 212-219, 2020202
10
2020
Estimating the transmission dynamics of Omicron in Beijing, November to December 2022
K Leung, EHY Lau, CKH Wong, GM Leung, JT WumedRxiv, 2022.12. 15.22283522, 2022202
9
2022

Referred From: https://scholar.google.com/citations?user=QojU1AoAAAAJ&hl=en

Cited by
Citations 12185
h-index 61
i10-index 170
Recommended Journals
Open Access Journals